Tscan Therapeutics Inc

NASDAQ:TCRX

1.51

+0.04 (+2.72%)

4:48:05 PM EDT: $1.52 +0.01 (+0.66%)

Market Cap (Intraday)	87.78M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$1.31 Million
Adjusted EPS	-$0.33

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Tscan Therapeutics Inc Stock, NASDAQ:TCRX

830 Winter Street, Waltham, Massachusetts 02451

United States of America

Phone: +1.857.399.9500

Number of Employees: 194

http://www.tscan.com

Description

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.